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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre and any of their employees. Sections of 
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AU  African Union 
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OIE  World Animal Health Organization 
PCR  Polymerase chain reaction 
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Etiology and relevance 
Lumpy skin disease (LSD), a viral disease of cattle, was first described in Zambia in 1929, and is now endemic in 
most part of Africa. Characterised by significant morbidity although the mortality rate is generally low, losses 
occur from decreased milk production, abortion, infertility, loss of condition and damaged hides. The economic 
impact of LSD on livestock production in Africa is so high that the disease has been selected as one of 14 
diseases impacting negatively on poor livestock keepers on the continent, with annual losses estimated at USD 
487 million. Lumpy skin disease virus (LSDV) is a capripoxvirus, of the genus Capripoxvirus, in the family 
Poxviridae. LSDV is closely related antigenically to sheep and goat poxviruses. Although these three viruses are 
distinct, they cannot be differentiated with routine serological tests. 
A double-stranded DNA virus, LSDV, like other poxviridae, has a large size, an attribute that has been extensively 
exploited to use this virus as vector for expressing foreign viral genes and generating recombinant multivalent 
vaccines. Another potentially beneficial attribute of the LSDV is its remarkable stability and ability to survive for 
long periods at ambient temperature, especially in dried forms. The virus is also is very resistant to inactivation. 
 
Epidemiology and transmission 
LSD is a disease of cattle, with Bos taurus bieng more susceptible to clinical disease than Bos indicus. The role of 
wild fauna is still not clear. Some animals, such as the giraffe and impala are highly susceptible to experimental 
infection and suspected clinical disease has been described in certain type of wild animals; antibodies have also 
been found in African buffalo, greater kudu, waterbuck, reedbuck, impala, springbok, and giraffe. Following 
inoculation LSDV replicates in sheep and goats. 
The primary method of transmission is mechanical by arthropod vector. Though no specific vector has been 
identified to date, mosquitoes (e.g. Culex mirificens and Aedes natrionus) and flies (e.g. Stomoxys calcitrans and 
Biomyia fasciata) are believed to play a major role in transmission of the virus. Other possible and minor source 
of transmission could be direct contact, and ingestion of feed and water contaminated with infected saliva. 
From being restricted to Sub-Saharan Africa where it has been endemic, LSD is currently occurring on almost the 
entire African continent, has spread to the Middle East and entered Europe where it is currently present in 
Turkey and Greece. It has also been reported in the northern Caucasus region of Russia, Dagestan and Chechnya. 
LSD is feared now to have the potential to become established in other parts of the world. 
With an incubation period in the field believed to be from 2 to 5 weeks, the clinical signs of LSD range from 
inapparent to severe. Host susceptibility, dose and route of virus inoculation affect the severity of disease. 
Following a period of fever, the nodules on the skin start appearing within two days and are the most 
Lumpy Skin Disease | Monograph 23 






characteristic sign of LSD. The nodules expand also to mucous membranes and internal organs. Enlarged lymph 
nodes, edema of the skin, and sometimes death follow. Secondary bacterial infections are common within the 
necrotic cores. Decreased feed intake in affected cattle would result in milk yield dropping markedly, and 
animals becoming emaciated. Pregnant animals may abort. Permanent or temporary infertility may occur in 
bulls due to subsequent orchitis and testicular atrophy. An important point for trade is the fact that the virus can 
be excreted in the semen for prolonged periods. 
Immunity to LSD is predominantly cell mediated and requires a replicating agent to be effectively stimulated. In 
infected animals, the virus spread from cell to cell, thus is out of reach of circulating antibodies. Subsequently 
circulating antibodies can only limit the spread of the virus in experimental animals, but do not prevent 
replication of the virus at the site of infection. Furthermore, the immune status of a previously infected or 
vaccinated animal cannot be related to serum levels of neutralising antibodies. 
 
Diagnostics 
Clinically a presumptive diagnosis of the disease can be made based on highly characteristic clinical signs of LSD, 
although mild and asymptomatic disease may be difficult to diagnose and rapid laboratory methods are needed 
to confirm the diagnosis. 
It is always important to differentiate LSD from other skin pseudo LSD (bovine herpesvirus-2, BHV-2), insect 
bites, Demodex infection, onchocerciasis, besnoitiosis and dermatophilosis. 
At laboratory level the identification of the agent relies mainly on genome detection through PCR, electron 
microscopy of biopsy or crusts, and virus isolation. There is also the antigen ELISA that has been described. 
Serological tests include virus/serum neutralisation (golden standard test for serology), indirect fluorescent 
antibody test, capripox antibody ELISA and seldom Western Blot. Most serological tests however would not 
differentiate between different capripox. 
 
Control 
There is no specific treatment for LSD though strong antibiotic therapy may avoid secondary bacterial infections. 
Free countries are urged often to restrict import of livestock, carcasses, hides, skins and semen from infected 
countries or regions with ongoing enzootic situation. Sanitary prophylactic measures in infected countries or 
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Vaccination and vaccination strategies 
Only live attenuated vaccines are currently commercially available for LSD. They are either homologous LSDV or 
heterologous based on attenuated SGP strains. The attenuated Neething strain, the first LSD vaccine strain to be 
developed (in South Africa) is widely used on cattle in Africa, with the Kenya sheep and goat pox (KSGP or KS- 
1) used for both LSD and SGP. Other SGP vaccine strains exist and are also used in some regions for LSD. 
However it is known that the cross-protection is not satisfactory and the use of these vaccines has been 
restricted to those countries where sheep and goat pox are endemic. The Neethling and KSGP based vaccines 
are produced by several African vaccine manufacturing laboratories. In recent years several Middle East 
countries have also been producing vaccine based essentially on SGP strains. 
Even though the development of improved LSD vaccines has not been a major priority by many research groups 
or countries, capripox have been considered over the past two decades as ideal recombinant vaccine vectors 
due to their size and stability, thus good to express foreign genes. Recombinant LSD or KS-1 expressing PPR, 
rinderpest or rabies genes have been assessed, although no such commercial vaccine exist to date. 
Increased interest and concern on the effectiveness of the LSD vaccines have been raised over the past few 
years due to the spread of LSD into more countries in Asia and Europe, and to the lack of protection observed in 
countries such as Ethiopia with the locally produced vaccine. Several studies have been conducted and more are 
ongoing to assess the suitability of the different vaccines used for the control of LSD. In parallel, research on new 
generation LSD vaccines is looking into 4 options, namely (1) the use of LSD as a vector for expression of foreign 
genes and generation of multivalent vaccines; (2) the generation of attenuated vaccines by knocking out virulent 
genes but maintaining the immunogenicity; (3) the development of DIVA vaccines by knocking out non-essential 
but immunogenic genes and (4) the development of non-replicating vaccines (inactivated vaccines). 
 
The future of LSD vaccines and vaccination 
The new interest on LSD due to the risk the disease is posing for Europe is directing vaccine research toward 
solutions for preventing the introduction of the disease, rather than the control in endemic regions. There is a 
drive to ensure the availability of LSD vaccines that prevent infection and spread of the wildtype virus, and also 
have DIVA characteristics. Some of these characteristics, such as DIVA, may not be relevant for endemic regions. 
In most of these regions, where the disease has been causing serious economic losses, the main challenge is the 
availability of the vaccine and the lack of clear vaccination programs and strategies. 
It seems also very critical that the vaccines used in endemic regions be produced for virus seed materials 
properly evaluated, including at molecular level to confirm their identity, especially for the main homologous 
vaccine in use, the Neethling strain, but also produced under required quality standards and protocols. The 
availability and inclusion of such vaccine in well validated control program is a matter of priority, more than 
product characteristics such as DIVA. 
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Lumpy skin disease (LSD, also called Pseudo-urticaria, Neethling virus disease, exanthema nodularis bovis, and 
knopvelsiekte) is an infectious disease of cattle. It is caused by a virus (LSDV) from the family Poxviridae which is 
divided into two subfamilies— poxviruses affecting insects (Entomopoxvirinae) and vertebrates 
(Chordopoxvirinae)—and several genera. The genus Capripoxvirus (CaPV) comprises LSDV, sheep pox virus (SPV) 
and goat pox virus (GPV). Although the disease was first seen in Zambia in 1929, the prototype of LSDV, 
Neethling strain, was isolated in South Africa [5][11]. 
Poxviruses are large (320–260 nm), they can be enveloped or non-enveloped, brick- or oval-shaped viruses with 
similar morphology (except certain members of the group such as the parapoxviruses) [5]. LSDV is a double- 
stranded DNA virus, with a 151 kbp genome consisting of a central coding region with identical 2.4-kbp inverted 
terminal repeats and 156 putative genes. The genes encoding host range, virulence and immune evasions are 
located at the terminal parts of the genome [4]. It has been shown by DNA analysis using restriction 
endonucleases on field samples and vaccine strains that there is 80 % homology between strains of 
capripoxviruses [7]. The genomes of SPV and GPV are very similar to that of LSDV, sharing 96 % nucleotide 
identity within the genus [4][7]. It is not possible to distinguish between different strains of CaPV using serological 
assays [12]. Molecular studies have demonstrated that LSDV, SPV and GPV are phylogenetically distinct [4][7] and, 
recently, by sequencing the host-specific G-protein-coupled chemokine receptor (GPCR), or RNA polymerase 
genes, species-specific molecular assays have been developed for differentiation of CaPVs, enabling the 
phylogenetic grouping of CaPVs [4] 
LSDV is known to be remarkably stable; surviving for long periods at ambient temperature, especially in dried 
forms, and is very resistant to inactivation: it can be recovered from skin nodules kept at –80C°C for 10 years and 
infected tissue culture fluid stored at 4°C for 6 months. The virus can survive in necrotic skin nodules for up to 33 
days or longer, desiccated crusts for up to 35 days and at least 18 days in air-dried hides [5][7]. It can remain viable 
for long periods in the environment. Meanwhile, the virus is susceptible to sunlight and detergents containing 
lipid solvents, while, in dark environmental conditions, such as contaminated animal sheds, it can persist for 
many months [11]. 
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Susceptible animal species 
• LSD is a disease of cattle (Bos taurus, zebus, domestic Asian buffalo). Bos taurus is more susceptible to 
clinical disease than Bos indicus. 
• Natural infections in Asian water buffalo (Bubalus bubalis) have been reported in Egypt, but with 
significantly lower prevalence rate (1.6 %) than in cattle (30.8 %) [11][12]. 
• Lumpy skin disease virus replicates in cell cultures of sheep and goat origin. In experimentally infected 
sheep and goats there is local reaction at the inoculation site, but there are no reports on clinical disease 
in small ruminants caused by LSDV. 
• Clinical signs of LSD have been demonstrated in impala (Aepyceros melampus) and giraffe (Giraffa 
camelopardalis) after experimental inoculation with LSDV. LSD was reported in an Arabian oryx (Oryx 
leucoryx) in Saudi Arabia [11]. 
• Antibodies against capripoxes have been detected in blue wildebeest (Connochaetes taurinus), black 
wildebeest (Connochaetes gnu), springbok, eland (Taurotragus oryx) and impala. The seroprevalence 
varied from 10 to 27 %, averaging 17 % in a grassland and 33 % in a forest transition environment 
(Barnard, 1997). Antibodies were also detected in serum samples collected from African buffalo 
(Syncerus caffer) in Kenya [5][11]. In another study, low levels of antibodies were detected in kudu 
(Tragelaphus strepsiceros), two waterbuck species (Kobus ellipsiprymnus and Kobus defassa), reedbuck 
(Redunca arundinum), impala, springbok and giraffe, leading to the conclusion that the samples may 
have contained non-specific virus inhibitors. However, the antibody titres in the giraffe and reedbuck 
samples were as high as in convalescent cattle that were assumed to be indicative of past infection [5][11]. 
 
Distribution 
LSD has traditionally been restricted to sub-Saharan Africa but over the past 15 years has spread to most African 
countries, the Middle East and some European countries. The outbreaks outside Africa started with those in the 
Middle East between 2006 and 2007, and in Mauritius in 2008. Between 2012 and 2013 the disease spread in 
Northern Israel and Libanon. Between 2013 and 2015 it spread further: was first reported in Turkey, and in 
2015, the first incursion of LSDV was reported in the European Union territory in Greece, close to the river Evros 
and the Turkish border. It has since been reported in the northern Caucasus region of Russia, Dagestan and 




Lumpy Skin Disease | Monograph 23 









Figure 1: Map showing number of years of presence of LSD in different countries as reported to OIE for the 
period 2005–2013 (EU). 
 
Transmission 
It is currently believed that the main mode of transmission of LSDV is mechanical via blood-feeding insects with 
frequent feeding habits [11]. The most important vector is likely to vary between affected regions, depending on 
the climate, season, environmental temperature, humidity and vegetation, favouring different insect and tick 
species. The relative importance of vectors may also vary within a region as changes in climate may affect the 
local arthropod populations and viral spread [7]. 
The virus has been recovered from Stomoxys spp. and Musca confiscate although attempts at transmitting the 
infection with these flies were unsuccessful [12]. Other indirect evidence that a vector(s) is involved in the 
transmission of LSD is the failure of control measures, such as quarantine, to stop its spread both in South Africa 
and Kenya [5]. 
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The virus seems inefficiently transmissible directly between animals. Transmission through semen has been 
demonstrated experimentally. Transmission may also occur by ingestion of feed and water contaminated with 
infected saliva [7][11] 
Recent data have shown molecular evidence of transstadial and transovarial transmission of LSDV by 
Rhipicephalus decoloratus ticks, and mechanical or intrastadial transmission by R. appendiculatus and 
Amblyomma hebraeum ticks [1]. 
 
Immunity to LSD 
Serological studies with cattle vaccinated with sheep and goat poxvirus have shown that many animals resist 
challenge with virulent LSDV when they have no detectable fluorescent or neutralising antibody to the virus. 
Most animals do show a serological response after field infections. As is the case for most pox viruses, immunity 
to LSD is considered to be predominantly cell mediated and the immune status of animals does not directly 
correspond to serum neutralizing antibody titers [7]. 
With the exception of enveloped forms of the viruses, which are released into the blood, most progeny LSDV 
remain inside infected cells. By spreading from cell to cell, the virus is out of reach of circulating antibodies. 
Circulating antibodies against capripox virus are able to limit the spread of the virus in experimental animals, but 
do not prevent replication of the virus at the site of infection [1][7]. The immune status of a previously infected or 
vaccinated animal cannot be related to serum levels of neutralising antibodies. 
All capripoxes share a common major antigen for neutralising antibodies; animals recovered from infection by 
one virus are believed to be at least partially protected from infection with the other. It is not possible to 
distinguish CaPVs with the serum neutralisation test (SNT), fluorescent antibody test (FAT), indirect fluorescent 
antibody test (IFAT) or agar gel immunodiffusion (AGID) [11][12] 
Animals that recover from apparent or inapparent natural infection with LSD develop antibodies capable of 
neutralising up to 3 logs of the virus and are also resistant to reinfection, whereas those that have been 




The severity of clinical signs varies widely ranging from very mild to severe. Bos taurus cattle are more 
susceptible than Bos indicus (zebu) and lactating cows and fine-skinned dairy breeds, such as the Guernsey and 
Jersey, are particularly susceptible [5][11] 
In acutely affected animals the first symptoms are fever followed by development of swellings or nodules in the 
skin that give the disease its name (Figure 2). These nodules are 2-5 cm across and occur in particular on the 
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head, neck, udder and perineum. The nodules, which can number many hundreds, are painful, affecting the skin, 
subcutaneous tissue and sometimes the underlying muscle and can become necroctic causing deep cratered 
scars. Other symptoms include a marked reduction in milk yield, depression, anaemia, excessive salivation and 
ocular and nasal discharge. Pox lesions are also present in the mouth, nose, testicles and bladder. The superficial 
lymph nodes, draining areas of affected skin, are significantly enlarged and the limbs can become swollen 
causing the animals to be reluctant to move. Secondary bacterial infections are common affecting the teats, 
tendons and joints and fly strike can occur at the site of the skin lesions. Abortions can occur and the aborted 
foetuses have sometimes been reported to also be covered in nodules. Affected bulls and cows can become 




Figure 2: Lumpy skin disease in cattle. [12] 
 
Recovery from LSD is slow, essentially due to emaciation, pneumonia, mastitis, and necrotic skin plugs, which 
are subject to fly strike and shed leaving deep holes in the hide: it can take as long as 6 months [5][11]. Mortality 
rates vary: some reports suggest average rates of 1-3% in zebu and around 10% in dairy breeds. In an epizootic 
of LSD that occurred between 1981 and 1986 in Tanzania, Kenya, Zimbabwe, Somalia and the Cameroon, 
mortality rates of 20% of affected cattle were reported. Deaths are probably largely due to secondary bacterial 
infections [5][6][11]. 
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Nodules are characteristics and involve all layers of skin, subcutaneous tissue, and often adjacent musculature, 
with congestion, haemorrhage, oedema, vasculitis and necrosis. Lymph nodes draining affected areas are 
enlarged, accompanied with lymphoid proliferation, oedema, congestion and haemorrhage. Pox lesions are 






Though field incubation period is not much described, in experimental infection, following inoculation the onset 
of fever is in 6–9 days, and first skin lesions appear at the inoculation site in 4–20 days [11]. LSD should be 
suspected when the characteristic skin nodules, fever and enlarged superficial lymph nodes are seen. Painful 
nodules of 2–5 cm in diameter develop over the entire body, particularly on the head, neck, udder and perineum 
between 7 and 19 days after virus inoculation. 
 
Differential Diagnosis 
Although severe LSD is highly characteristic, milder forms can be confused with diseases including pseudo-lumpy 
skin disease/ bovine herpes mammillitis (Bovine Herpesvirus 2), dermatophilosis, ringworm, insect or tick bites, 
besnoitiosis, ringworm, Hypoderma bovis infestation, photosensitization, bovine papular stomatitis 
(Parapoxvirus), urticaria and cutaneous tuberculosis. Most of these diseases can be distinguished from lumpy 
skin disease by the clinical signs, including the duration of the disease, as well as histopathology and other 
laboratory tests [11][12] 
 
Laboratory diagnosis 
• Confirmation of LSD in a new area requires virus isolation and identification. Samples for virus isolation and 
antigen-detection ELISA should be taken during the first week of signs, before neutralising antibodies have 
developed. Samples for PCR can be collected after this time [15]. In live animals, biopsy samples of skin 
nodules or lymph nodes can be used for PCR, virus isolation and antigen detection. Scabs, nodular fluid and 
skin scrapings may also be collected. In early, viraemic stages of the disease, blood samples can be 
collected for virus isolation 
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• The identification of LSDV can be achieved through: 
o PCR: on EDTA blood, semen, biopsy, or tissue culture samples. While the general capripox real- 
time PCR method is highly sensitive and specific, differentiation with other capripoxes may require 
sequencing and phylogenetic analysis [11][15] 
o Transmission electron microscopy: on biopsy material or desiccated crusts 
o Capripox antigen detection ELISA: on biopsy suspension or tissue culture fluid 
• Serological tests 
o Virus neutralisation – cross reacts with all capripoxviruses 
o Indirect fluorescent antibody test: cross reaction with parapoxviruses 
o Capripox antibody ELISA. 
o Western blot: highly sensitive and specific but expensive and is difficult to perform; it requires 
purified antigens, and cannot be used as a primary assay but can be used if inconclusive or positive 
SNT/ELISA results need to be confirmed [7][11][15] 
• Other tests described but not widely used are: 
o LSD penside test [7] 
o Loop-mediated isothermal amplification assays (LAMP), which have been published but are not yet 
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Incidence data by country 
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 1 and 2.  Data are 
not always reliable, as many countries doesn’t seem to report, or to be reporting consistently over time.  
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
Similar information but presented in a different manner can be seen in Annex 1. 
Table 1: Number of LSD outbreaks reported to the OIE between 2005-2015 (Numbers given only for the 
target countries). Source: OIE. 
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Burkina Faso 13 17 81 13 9 195 82 21 8 52 3 
Ivory Coast >1 0 + + + + + + 1 -  
Mali 2 5 >2 0 0 2 0 1 0 1 0 
Senegal 3 5 1 190 2 2 1 + 0 5 + 
East Africa 
Ethiopia 27 72 129 130 284 180 177 179 230 166 34 
Kenya + 0 9 0 0 0 0 3 9 24 9 
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Rwanda - 0 >4 12 >6 >4 + 51 54 - - 
Tanzania 138 41 99 19 12 12 10 10 25 37 7 
Uganda 7 ? ? ? ? ? + 2 3 >8 - 
Southern Africa 
Madagascar >52 16 26 + + 36 7 6 13 6 4 
Malawi >9 >12 26 >5 >3 5 1 24 34 - - 
Mozambique >4 >6 18 7 3 2 >4 1 0 0 - 
South Africa 17 156 229 153 54 56 213 92 56 127 18 
Zambia - 50 52 103 123 108 + 74 141 90 - 
 
- No information, +  Present but quantitative data not known,  ? Disease suspected 
 
2- AU-IBAR: The number of outbreaks reported to AU-IBAR is included in the Pan African Animal Resources Year 
Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=) and can be 
seen for the countries of interest in Table 2 below. 
 
Table 2: Number of LSD outbreaks reported to the AU-IBAR from 2005 to 2015 (numbers given only for the 
target countries). Source: AU-IBAR Year Books. 
 
Country 2005* 2006** 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Burkina Faso   53  7 195 82 20 8 52  
Ivory Coast            
Mali    11  2 1 1  1  
Senegal    190 3 1 1 2 26 4  
East Africa 
Lumpy Skin Disease | Monograph 23 






Ethiopia   275 420 1 341 187 197 337 131  
Kenya   51  5 53 
cases 
12 20 5 19  
Rwanda      14   14   






11 9 26 30  
Uganda   11 7 6 11 63 9 3   
Southern Africa 






43     
Malawi   23  3 2  21 38 2  
Mozambique   38  4 8 2  1 1  
South Africa   216 149 8 36 146 96 59 122  
Zambia   54 11 37 39 37 33 111 80  
 
*AU-IBAR didn’t start yet producing data for LSD 
**No individual country report available; 7 countries reported to a total of 334 outbreaks 
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Prevalence data by country 




















See    details    in    Figure 
below. 








393 Herd: 44 
Individual: 7.4 
Hailu et al, 2014 










Gari et al, 2012 
2011 Adama Traded   Borena 
Bulls 
11,189 6.1 Alemayehu et al,  
2012 
2010 15 Districts Questionnaires 
to herd owners 
330 Herd Total: 
42.8 
Midland agro-climate 
Gari et al, 2010 
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Figure 3: LSD seroprevalence by district in West Wollega. Source: Abera et al, 2015 PA: Peasant Associations 
 
South Africa 
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Fagbo et al,  
2014 
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Economic and Social Impacts at Global 







LSD impacts on cattle production and on a number of aspects: 
• Cattle are particularly susceptible to LSD during peak lactation, which together with secondary mastitis 
and prolonged high fever, affects milk production. 
• Abortions and temporary or permanent infertility occur among infected animals. 
• Emaciation and a long convalescence period can significantly decrease the growth rate in beef cattle. 
• More importantly, deep pox lesions in the skin leave permanent scars, decreasing the value of skins and 
hides for use in the leather industry [13] 
In a study by Gari et al. [8] conducted in dairy cattle in the in the highlands of the Oromia region, located near 
Addis Ababa, it was reported that the average duration of the lactation period of local zebu cows was shorter 
(240 days) than for Holstein Friesian/cross breeds (305 days) and for zebu cattle the milk take-off per lactation 
was significantly lower (323 l) than for Holstein Friesian/cross cows (3694 l). In this study comprising a selection 
of farms, the Holstein Friesian and Jersey breeds were found to be almost three times more susceptible for LSDV 
than zebus (annual cumulative incidence of LSDV infection of 33.93% and 13.41% respectively) and the annual 
mortality rates due to LSDV infection of zebus was considerably lower than for Holstein Friesian (1.26% 
compared to 7.43%). In addition, estimated total production losses in infected cattle due to decrease in milk and 
beef production, loss of draft power, mortality, veterinary treatments and vaccination costs were estimated to 
be 6.43 USD per head for local zebu and 58 USD per head for Holstein Friesian/cross breeds. 
In South Africa LSD has become one of the major causes of economic losses to non-commercial communal cattle 
owners [10] 
As part of their disease prioritization effort, the Bill and Melinda Gates Foundation identified LSD as one of 14 
diseases that negatively impact on poor livestock keepers. The total annual losses to small farmers in Africa due 
to LSD were calculated to be USD 487 million [16]. 
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There is no treatment for Lumpy Skin Disease although antibiotic therapy may prevent severe secondary 




In theory, control of the disease can be achieved by implementation of strict quarantine and effective 
movement controls, slaughter of infected and in-contact animals, proper disposal of carcases, disinfection of 
affected premises and vector control [11]. The outbreak in Israel in 1989 was rapidly eliminated by a combination 
of these methods together with vaccination [7]. In Africa, however, lack of capacity in the veterinary services and 
the difficulties of enforcing quarantine and movement restrictions in remote areas means that this approach has 
proven to be generally ineffective. Important to note that no country in sub-Saharan Africa, however, has 
succeeded in eradicating LSD once it has occurred [7] 
As biting flies are most probably the most important method of transmission of the disease, control by 
quarantine and movement control  is generally  not very effective.  In endemic areas control  is therefore 
essentially confined to vaccination [5]. 
When LSD appears in a new area, non-enzootic, it is recommended that all infected and contact cattle be 
slaughtered immediately and the carcasses destroyed in an attempt to eliminate the focus of infection. A 
vaccination cover with a 25 to 50 km radius may then be established around the focus and all cattle movements 
stopped within that zone. Alternatively, it might be decided to leave all cattle in the zone unvaccinated, allowing 
the manifestation of any- residual infection [6] 
When an outbreak occurs in an enzootic area and LSD has already spread extensively, slaughter policies- are 
inappropriate and extensive vaccination campaigns are recommended. The imposition of strict movement 
controls are suggested because, although these do not contain outbreaks of LSD, they do prevent new foci from 
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becoming established at a certain distance. Vaccination will greatly reduce the morbidity and economic effects 
of an epizootic but may not completely limit the extension of-LSD. Follow-up vaccination of calves and re- 
vaccination programmes over a period-of two to three years will greatly reduce the incidence of clinical disease 
[6][11]. 
Animals that recover from infection with any strain of capripoxvirus, whether of bovine, ovine or caprine origin, 
are resistant to infection with any other capripoxvirus strain. It is therefore possible to protect cattle against LSD 
using strains of capripoxvirus derived from sheep or goats [7][11], although the level of protection is not the same, 
as described later in this document. 
Two live attenuated strains of capripoxvirus are the most widely used as vaccines for the control of LSD: a 
Kenyan strain of Sheep Pox virus (KSGP or KS-1) and a cattle strain of LSDV (Neethling type) from South Africa 
[5][15]. Vaccination is believed to trigger lifelong protection. Both strains of capripoxvirus used as vaccines can 
produce large local reactions at the site of inoculation in Bos taurus breeds, which discourages the use of the 
vaccine and increases the size of the susceptible population [5]. Other capripox vaccine strains have also been 
developed. 
 
Disease situation and government policies by country 
Tables 3 and 4 below have been completed with the information received so far from the questionnaires sent to 
the DG and DVS.  
Table 3 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation. Table 4 refers to vaccination. 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection,  collation  and analysis of data  and  the timely dissemination 
of information to those who need to know so that action can be taken. 
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
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Table 3: Official status, official programs for LSD in the countries of interest. Information provided by the 






















Burkina Faso      
Côte d'Ivoire 
(Ivory Coast) 
Yes Yes, passive but 
active if 
outbreaks 
Yes Yes If animals are 
sick 
Ethiopia      
Kenya Yes Yes, passive No No No 
Madagascar      
Malawi Yes Yes, passive No N/A N/A 
Mali Yes Yes, passive No No No 
Mozambique      
Rwanda - - - - - 
Senegal      
South Africa      
Tanzania Yes Yes, passive No No No 
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Table 4: Vaccination for LSD in the countries of interest. Information provided by the questionnaire sent to 
the DG/DVS as part of this monograph. 
 















(cattle, sheep, goats, 
pigs, poultry) 
Burkina Faso     
Côte d'Ivoire 
(Ivory Coast) 
 Farmer Private Cattle 
Ethiopia     
Kenya No Farmer Both Cattle 
Madagascar     




Mali No Combination Official Cattle 
Mozambique     
Rwanda - - - - 
Senegal     
South Africa     
Tanzania No Farmers, private Private Cattle 
Uganda No Combination Both Cattle 
Zambia Yes Combination Official Cattle 
 
Note that Zambia is the only country that has reported compulsory vaccination. 
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Current vaccine types 
Only live attenuated vaccines are currently commercially available against LSD. They are generally cheap and 
provide good protection if sufficient herd immunity (over 80%) is maintained by carrying out annual 
vaccinations. 
Broadly the current live attenuated vaccines used against LSD can be grouped into homologous vaccines (the 
Neethling and KS-1), and the heterologous, which are SGP strains (Table 5) 
Table 5: The different types of vaccines used for LSD and their strains [3] 
 
Disease Capripox vaccine strain Major animal targeted Comments 
SGP Romania (SPV) Goats & sheep  
 RM-65 (SPV)  Used in cattle at x10 the SG dose 
 Mysore (GPV)   
 Gorgan 5GPV)   
 KS-1 /O240 (LSDV)   
LSD Neethling strain (LSD) Cattle  




Two vaccine strains have been widely and successfully used for decades in the prevention of LSD in cattle 
populations in Africa: the LSD Neethling virus strain virus, and the Kenya sheep and goat pox virus vaccine. There 
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are however other strains currently in use in other part of affected regions, of which the Yugoslavian RM 65 
sheep pox strain and Romanian sheep pox strain are most common [15]. The vaccines commercially available and 
licensed for LSD are listed in table 7 below. 
LSD Neethling strain vaccine 
• Developed in South Africa, and used for decades in Southern Africa, the Neethling strain of LSD was 
passaged 50 times in tissue cultures of lamb kidney cells and then 20 times on the chorio-allantoic 
membranes of hens' eggs; for production the vaccine virus is now propagated in cell culture [5][6]. Annual 
vaccination is recommended. 
• According to Coetzer [5], approximately 50% of cattle develop a swelling 10 to 20 mm in diameter at the 
point of inoculation and this may be accompanied by a temporary drop in milk yield in dairy cows. The 
swelling disappears within a few weeks. Animals younger than six months of age whose dams were 
either naturally infected or immunized should not be vaccinated, in order to prevent interference from 
maternal antibody. However, calves born to susceptible cows are themselves very susceptible and 
should be vaccinated as soon as possible in the face of an outbreak. 
• Besides OBP and MSD (actually produced by Design Biologics) in South Africa, the Neethling strain-based 
LSD vaccine is currently also produced by NVI in Ethiopia. A modified strain is also produced by 
Deltamune in South Africa. 
 
Kenyan sheep and goat pox (KSGP) 
• Also referred to as Kenyan O240 strain or KS-1 strain. 
• Developed in Kenya the KS-1 was passaged 16 times in pre-pubertal lamb testes or foetal muscle cell 
cultures [6]. 
• Although derived from a sheep isolate and passaged in lamb testis and baby hamster kidney (BHK) cells, 
further genomic studies have shown that the strain had a closer nucleic acid identity to LSDV than to 
SPV or GPV, suggesting that this sheep-derived capripoxvirus virus is in fact a strain of LSDV [4][9]. 
• As seen with other sheep and Goat pox vaccine when used in cattle for LSD, incomplete protection 
against LSD has been reported in cattle vaccinated with KSGP [13]. The low level of attenuation for safe use 
is insufficient for cattle and, in some cases, the vaccine has been observed to still be virulent [7][13]. 
• The KSGP has never been used or recommended for use in Southern African countries free of SGP, as it 
was believed to otherwise provide a source of infection for the susceptible sheep and goat populations 
[5]. Its use as vaccine against LSDV has been restricted to those countries where SPP, GTP and LSD 
overlap, such as central, Eastern, Western and northern Africa, the Middle East, Turkey, Iraq and Iran. 
• The finding that the KSGP is actually an LSD strain should no longer restrict its use for LSD. MCI Santé 
Animale produce an LSD vaccine (BOVIVAX) based on the KSGP strain, while several African government 
vaccine manufacturers produce a KSGP vaccine for use against LSD and SGP (Table 6). 
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The other strains used as LSD vaccine 
• The Yugoslavian RM65 SPPV vaccine, at a 10 times higher dose than indicated for sheep, has commonly 
been used for cattle across the Middle East. 
• In Egypt both the Romanian SPP and Kenyan sheep and goat pox (KSGP) virus vaccines have been used 
for cattle [6][13]. 
• The Bakirkoy SPV (at three to four times the recommended dose for sheep) has been used in Turkey 
against LSDV [13]. 
 
It is important to note that incomplete protection against LSD has been reported in cattle vaccinated with sheep 
pox derived vaccines [13]. 
 
Neutralizing antibodies to LSDV persist for at least two to three years after vaccination. In some animals, the 
antibody levels are too low to demonstrate, but they are, nevertheless, still resistant to challenge [5]. Antibodies 
appear 10 days after vaccination and reach the highest level 30 days post inoculation. Calves born to immunised 
cows will have passive immunity that persists for about six months [5]. 
 
Challenges with current vaccines 
There have been different reports on safety and efficacy of the different Capripox vaccines used for protection 
against LSD. Generally, sheep and goat pox vaccine strains tend to have limited efficacy when used in cattle for 
LSD, and generally are given at a higher titer [4][7][13]. 
 
Recently several reports have been published reporting LSD vaccine failure in Ethiopia. The LSDV Neethling and 
KSGP O-180 strain vaccines, both produced locally by the National Veterinary Institute (NVI) are used in cattle 
against LSDV in Ethiopia [2][3][8][13]. In 2008 and 2009 re-infection of vaccinated animals was observed during LSDV 
epidemics. The highest morbidity (15.1%) and mortality (5.37%) of LSD were observed in vaccinated feedlot cattle 
rather than in extensively managed cattle [2]. Another study in Ethiopia reported morbidity and mortality rates 
of 22.9% and 2.31% respectively in fully vaccinated herds [3]. Similar vaccine failure has been reported in sheep 
vaccinated against SGPV using the NVI KSGP O-180 vaccine [13], highlighting the need for molecular 
characterization of the vaccine seed viruses and re-assessment of the level of attenuation of the local vaccines. 
 
Recently, Gari et al. [8] compared the efficacy and immunogenicity of NVI LSDV Neethling and KSGP O-180 strain 
vaccines and the Gorgan GTP strain vaccine (CaprivacTM, Jordan Bio-Industries Center, Amman, Jordan) 
produced by the Jordan Bio-Industries Centre (JOVAC). The study included vaccine challenge experiments in a 
controlled environment and monitoring of immune responses in vaccinated animals in the field. The Ethiopian 
Neethling and KSGP O-180 vaccines failed to provide protection in cattle against LSDV, whereas the Gorgan GTPV 
vaccine protected all the vaccinated calves from clinical signs of LSD. Moreover, the Gorgan GTPV vaccinated 
cattle showed higher levels of cellular immune responses at the vaccination site, consistent with greater 
immunogenicity [8]. 
 
It is important to note that there is no indication on whether the poor results seen with the NVI Neethling vaccine are 
linked to the product quality or to the strain itself. As stated earlier in this section, it will be important, among other 
things, to conduct further evaluations, including molecular characterization, of the vaccine seed viruses and re-
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assessment of the level of attenuation of the local vaccines. 
 
Following the use of the vaccine in Israel during the different outbreaks that occurred a study was conducted by a team of 
the Koret School of Veterinary Medicine, Hachaklait (Prof. Eyal Klement), where the OBP Neethling vaccine was compared 
to 10x dose of RM65 strain vaccine from Jovac and ABIC. From the results obtained, it was concluded that the Neethling 
vaccine had a better relative effectiveness than the RM65 in preventing LSD in cows when full immunity is anticipated, and 
in preventing severe and confirmed LSD cases. The Neethling strain was able to cause non-severe disease in a proportion 
of animals, and could also spread to non-vaccinated animals. 
 
 
Commercial vaccines manufactured in Africa and Asia  
 
Table 6: Lumpy skin disease vaccines manufactured in Africa  
 
Vaccine name Manufacturer Hosts Pathogens vaccinated against 
Herbivac LS Deltamune Cattle Lumpy skin disease [Neethling] virus 
(Attenuated) 
LUMPIVAX Kenya Veterinary 
Vaccines Institute- 
KEVEVAPI 






Institute of Ethiopia (NVI) 
Cattle Neethling (Attenuated) 
Lumpy Skin Disease 
Vaccine for Cattle 
Onderstepoort Biological 
Products Ltd. 
Cattle Lumpy skin disease [Neethling] virus 
(Attenuated) 
Lumpyvax MSD Animal Health 
[Intervet, Schering- Plough 
Animal Health, Merck Sharp 
& Dohme, Coopers Animal 
Health] 
Cattle Lumpy skin disease [Neethling] virus (SIS 
type) (Attenuated) 
CaprivacTM Jordan Bio-Industries 
Centre (JOVAC) 




Veterinary Serum and 
Vaccine Research Institute 
- Egypt 
Cattle Strain not mentioned 
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 ABIC Israel Cattle Yugoslavia RM65 (10x sheep dose in cattle 
NODULOVAX LANAVET; Garoua, 
Cameroun 
Cattle KSGP strain; also for SGP 
DERMAPOX LCV Bamako, Mali Cattle KSGP strain; also for SGP 
CLAVESEC ISRA Senegal Cattle No strain information 




Commercial vaccines imported into Africa and Asia 
 
The information summarised in Table 7, is based on a questionnaire send to the Director of Veterinary Services 
office and regulators of the countries of interest. Note that some vaccines might have been imported under DVS 
dispensation, and they are not necessary licensed in the country. 
To the best of our knowledge, none of the target countries, in the exception of South Africa, Zambia and to a 
limited extend Mozambique, practices vaccination. 
 






















Burkina Faso        
Côte d'Ivoire 
(Ivory Coast) 
- - - - - - - 
Ethiopia        
Kenya - - - - - - - 
Madagascar        
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Malawi N/A N/A N/A N/A N/A N/A N/A 
Mali N/A N/A N/A N/A N/A N/A N/A 
Mozambique        
Rwanda - - - - - - - 
Senegal        
South Africa        
Tanzania * Attenuated 
LSD 
 South Africa 30    
Uganda*   Kenya 10,000 24,000 0 20,000 
Zambia   South Africa 291,500 110,000 42,100  
 




JOVAC, the manufacturer from Jordan was also sent a questionnaire designed for key importers into the region. 
They confirmed that they export LSD vaccine (Jovivac Strong), strain RM-65 to Asia and Africa. They did not specify 
the countries or the volumes. 
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The recent spread of LSD toward Europe has triggered increased focus on vaccines more suitable for non- 
endemic areas, preferably non-replicating, DIVA, with increased focus on safety. Enzootic regions however, 
which represent most of the African continent, need preferably efficacious, affordable and available LSD 
vaccines. In addition to the availability of such vaccines, these regions need vaccination programs that are 
implemented and adopted in all livestock communities. 
Table 8: Vaccine imported into the different countries  
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen Immunogen with protective antigens of 
capripox viruses that protects against 
LSD infection 
Immunogen capable of providing full 
protection in cattle against LSDV 
infection 
2 Indication for use For active immunization of cattle & 
water buffaloes 
For active immunization of cattle, 
water buffalos and all susceptible 
animals 
3 Recommended species Cattle, Water buffaloes All LSD and capripox susceptible 
livestock 
4 Recommended dose 2 ml 1 ml 
5 Pharmaceutical form Reconstituted injectable 
solution/suspension (freeze-dried 
vaccine) or ready to use solution 
(inactivated vaccine) 
Ready to use solution/suspension 
6 Route of administration intramuscular SC, Intramuscular or pour on 
7 Regimen - Single dose Single lifetime dose 
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8 Regimen - booster Single annual booster Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against all geographically 
distinct strains of LSD 
Protection against capripoxes and 
prevention of virus transmission 
10 Recommended age at 
first vaccination 
Animals over 3 months: one injection From 1-2 months of age 
11 Onset of immunity 2-3 weeks following primary 
vaccination 
One week following primary 
vaccination 
12 Duration of immunity At least 1 year Lifelong immunity 
13 Expected efficacy To prevent disease & prevent 
mortality. 
To prevent infection and transmission. 
No disease & no mortality in vaccinated 
animals after virulent challenge. 
14 Expected safety In animals under 6 months of age, a 
transient pyrexia reaction can occur. A 
transient nodular reaction of varying 
importance, may appear at the 
injection site, it progressively 
disappears within 1 to 2 months. 
Only vaccinate pregnant animals on 
emergency. 
No post-vaccinal reactions at any age. 
Safe for pregnant animals. 
No carrier form in vaccinated animals 
15 Withdrawal period Nil Nil 
16 Special requirements 
for animals 
Do not vaccinate un-healthy animals Do not vaccinate un-healthy animals 
DIVA 
17 Special requirements 
for persons 
None None 
18 Package size 50 doses Multiple pack size from 50 doses 
19 Price to end user Not more than $0.50/dose $0.20/dose at end user 
20 Storage condition and 
shelf-life as packaged 
for sale 
12 months at 4-8° C 24 months 4-8° C and/or 48 hours at 
30° C 
21 In-use stability 1 hour 24 hours 
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Overall conclusion for improved LSD control through vaccination 
• The spread of LSD toward Europe is triggering increased interest in the development of more efficacious 
and safer vaccine that could prevent infection and spread of the wildtype virus, and also have DIVA 
characteristics. All vaccines available to date have been live attenuated and not always possessing these 
characteristics. 
• The work initiated several years ago in South Africa, CIRAD and PIrbright (UK) for the development of a 
capripox vector expressing foreign genes, but still being able to immunise against LSD is being boosted, 
also taking advantage of continuous scientific progress. 
• In most endemic countries, where the disease has been causing serious economic losses, the main 
challenge is the availability of the vaccine and the lack of clear vaccination programs. 
• It seems also very critical that good quality vaccines, especially the only homologous currently available, 
the Neethling strain, be made available and used in highly affected regions. In these regions, a DIVA 
vaccine may not be a priority 
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ANNEX 1: Additional data on disease presence 
and incidence 
Reports to OIE on LSD: 
 
When different animal health statuses between domestic and wild animal population are provided, the 
box is split in two: the upper part for domestic animals, and the lower part for wild animals. 
LSD in Eastern Africa: Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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LSD in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
LSD in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
